S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

BACKGROUND: Immunotherapy with PD-1 antibodies has greatly increased prognosis of patients with advanced melanoma. Identifying biomarkers that predict overall survival (OS) and response to immunotherapy is important. METHODS: OS and best overall response according to RECIST version 1.1 were analysed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Nikolaus B, Forschner, Andrea, Leiter, Ulrike, Garbe, Claus, Eigentler, Thomas K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070917/
https://www.ncbi.nlm.nih.gov/pubmed/29950611
http://dx.doi.org/10.1038/s41416-018-0167-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070917/
https://www.ncbi.nlm.nih.gov/pubmed/29950611
http://dx.doi.org/10.1038/s41416-018-0167-x

Ejemplares similares